BJDX — Bluejay Diagnostics, Inc.
—
Nasdaq ·
Health Care ·
Health Care Equipment & Supplies ·
CIK 1704287 ·
Last close
$1.93
Market Cap
$2.00M
52W High
$2.13
52W Low
$1.62
ADV30
26,159
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 0 | — | -1,938,831 | -1,919,241 | 5,598,603 | 3,684,457 | 1,417,408 |
| Dec 2025 | 0 | — | -1,461,747 | -1,429,812 | 7,119,237 | 5,164,875 | 1,143,948 |
| Sep 2025 | 0 | — | -1,616,947 | -1,597,632 | 4,890,258 | 3,082,268 | 1,197,476 |
| Jun 2025 | 0 | — | -1,985,361 | -1,956,604 | 6,403,258 | 4,443,076 | 1,113,027 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-6,053,575
Investing CF
$-173,735
Financing CF
$7,090,240
CapEx
$-1,352
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-330.92
As of
2026-05-10
Balance + Analyst (yfinance extras)
Retained Earnings
$-41,517,267
Inventory
—
Receivables
—
ST Investments
—
EBIT TTM
$-6,872,356
Pretax Income TTM
$-6,848,483
Interest Exp TTM
$1,338
Analysts
—
Annual Trend (SEC EDGAR, last 5y)
Revenues vs Net Income (last 5y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -6,952,972 | -6,848,483 | 7,119,237 | 1,143,948 | — | -6,053,575 |
| Dec 2024 | 0 | -7,169,616 | -7,717,794 | 6,657,423 | 927,924 | — | -7,820,822 |
| Dec 2023 | 0 | -10,311,217 | -9,953,888 | 4,868,531 | 1,973,683 | — | -8,313,870 |
| Dec 2022 | 249,040 | -9,317,776 | -9,296,948 | 13,521,265 | 1,979,992 | — | -7,741,593 |
| Dec 2021 | — | — | — | — | — | — | — |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-0.32
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| PREM | Premier Air Charter Holdings Inc. | $1.90M | $0.06 | — |
| CUPR | Cuprina Holdings (Cayman) LTD | $1.81M | $0.25 | — |
| BBLG | Bone Biologics Corp | $2.26M | $1.26 | — |
| PFSA | Profusa, Inc. | $1.71M | $0.37 | — |
| VTAK | Catheter Precision, Inc. | $2.40M | $0.89 | — |
News headlines (Yahoo Finance, 1h cache)
Bluejay Diagnostics Provides First Quarter 2026 Corporate Update
2026-05-07 20:01 · Yahoo
Bluejay Diagnostics, Inc. Announces Completion of 624 Patient Enrollments in SYMON-II Pivotal Clinical Trial
2026-04-07 10:30 · Yahoo
Bluejay Announces Abstract Accepted for Presentation at the 2026 Society of Academic Emergency Medicine (SAEM) Annual Meeting
2026-03-12 10:30 · Yahoo
NorthStrive Fund II LP Issues Open Letter to the Board and Shareholders of Bluejay Diagnostics
2026-03-11 13:29 · Yahoo
Bluejay Diagnostics Provides Corporate Update and 2026 Strategic Outlook
2026-03-06 11:30 · Yahoo
Bluejay Diagnostics Announces All Prefunded Warrants Now Exercised
2026-02-20 11:30 · Yahoo
Bluejay Diagnostics Successfully Enrolls 545 Patients in SYMON™ II Study and Advances Manufacturing Readiness into 2026
2026-02-17 11:30 · Yahoo
Bluejay Diagnostics Announces 1-for-4 Reverse Stock Split
2026-01-27 13:00 · Yahoo
Bluejay Diagnostics Announces Completion of Commercial-Scale IL-6 Antibody Production
2025-12-29 12:00 · Yahoo
Bluejay Diagnostics Corporate Update: Advancing Clinical Milestones and Strategic Partnerships
2025-11-10 12:30 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.